Cargando…

DNA-Binding Anticancer Drugs: One Target, Two Actions

Amsacrine, an anticancer drug first synthesised in 1970 by Professor Cain and colleagues, showed excellent preclinical activity and underwent clinical trial in 1978 under the auspices of the US National Cancer Institute, showing activity against acute lymphoblastic leukaemia. In 1984, the enzyme DNA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baguley, Bruce C., Drummond, Catherine J., Chen, Ying Yi, Finlay, Graeme J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866126/ https://www.ncbi.nlm.nih.gov/pubmed/33494466 http://dx.doi.org/10.3390/molecules26030552

Ejemplares similares

Chromatin as a Target for the DNA-Binding Anticancer Drugs
por: Majumder, Parijat, et al.
Publicado: (2007)

The Role of the Hippo Pathway in Melanocytes and Melanoma
por: Kim, Ji Eun, et al.
Publicado: (2013)

Heterogeneity of expression of epithelial–mesenchymal transition markers in melanocytes and melanoma cell lines
por: Kim, Ji Eun, et al.
Publicado: (2013)

DNA topoisomerases as molecular targets for anticancer drugs
por: Buzun, Kamila, et al.
Publicado: (2020)

Intercalative DNA binding of the marine anticancer drug variolin B
por: Canals, Albert, et al.
Publicado: (2017)

One-pot synthesis of cyclic-aminotropiminium carboxylate derivatives with DNA binding and anticancer properties
por: Palai, Bibhuti Bhusana, et al.
Publicado: (2022)

Evidence for the Existence of Triple-Negative Variants in the MCF-7 Breast Cancer Cell Population
por: Leung, Euphemia, et al.
Publicado: (2014)

Keeping abreast with long non-coding RNAs in mammary gland development and breast cancer
por: Hansji, Herah, et al.
Publicado: (2014)

Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines
por: Leung, Euphemia Y., et al.
Publicado: (2015)

Epigenetic regulation in human melanoma: past and future
por: Sarkar, Debina, et al.
Publicado: (2015)

Signaling Pathways in Melanogenesis
por: D’Mello, Stacey A. N., et al.
Publicado: (2016)

Studies on the binding affinity of anticancer drug mitoxantrone to chromatin, DNA and histone proteins
por: Hajihassan, Zahra, et al.
Publicado: (2009)

Synthesis, Characterisation and Mechanism of Action of Anticancer 3-Fluoroazetidin-2-ones
por: Malebari, Azizah M., et al.
Publicado: (2022)

Novel DNA Bis-Intercalator XR5944 as a Potent Anticancer Drug—Design and Mechanism of Action
por: Buric, Adam J., et al.
Publicado: (2021)

Indolin-2-one compounds targeting thioredoxin reductase as potential anticancer drug leads
por: Kaminska, Kamila K., et al.
Publicado: (2016)

Targeting DNA Binding for NF-κB as an Anticancer Approach in Hepatocellular Carcinoma
por: Chung, Po Yee, et al.
Publicado: (2018)

Proteomic Approaches in Understanding Action Mechanisms of Metal-Based Anticancer Drugs
por: Wang, Ying, et al.
Publicado: (2008)

Anticancer drug mithramycin interacts with core histones: An additional mode of action of the DNA groove binder
por: Banerjee, Amrita, et al.
Publicado: (2014)

DSE-FRET: A new anticancer drug screening assay for DNA binding proteins
por: Miyagi, Toru, et al.
Publicado: (2014)

Cytokinetic factors in drug resistance of Lewis lung carcinoma: comparison of cells freshly isolated from tumours with cells from exponential and plateau-phase cultures.
por: Finlay, G. J., et al.
Publicado: (1987)

Two Targets, One Hit: new Anticancer Therapeutics to Prevent Tumorigenesis Without Cardiotoxicity
por: Szabó, Zoltán, et al.
Publicado: (2021)

Synthesis of novel coumarin nucleus-based DPA drug-like molecular entity: In vitro DNA/Cu(II) binding, DNA cleavage and pro-oxidant mechanism for anticancer action
por: Khan, Saman, et al.
Publicado: (2017)

Anticancer drug discovery by targeting cullin neddylation
por: Yu, Qing, et al.
Publicado: (2020)

Relationships between Signaling Pathway Usage and Sensitivity to a Pathway Inhibitor: Examination of Trametinib Responses in Cultured Breast Cancer Lines
por: Leung, Euphemia Y., et al.
Publicado: (2014)

Emerging Albumin-Binding Anticancer Drugs for Tumor-Targeted Drug Delivery: Current Understandings and Clinical Translation
por: Cho, Hanhee, et al.
Publicado: (2022)

Switchable conformational changes of DNA nanogel shells containing disulfide–DNA hybrids for controlled drug release and efficient anticancer action
por: Liwinska, Wioletta, et al.
Publicado: (2019)

A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency
por: Liu, Chuan, et al.
Publicado: (2015)

Targeting Colorectal Cancer Cells with Niosomes Systems Loaded with Two Anticancer Drugs Models; Comparative In Vitro and Anticancer Studies
por: El-Far, Shaymaa Wagdy, et al.
Publicado: (2022)

Screening DNA-targeted anticancer drug in vitro based on cancer cells DNA-templated silver nanoclusters
por: Zhang, Feng, et al.
Publicado: (2019)

Editorial for targets and anticancer drug research
por: .
Publicado: (2017)

Targeted Delivery Methods for Anticancer Drugs
por: Veselov, Valery V., et al.
Publicado: (2022)

Preliminary Evidence That High-Dose Vitamin C has a Vascular Disrupting Action in Mice
por: Baguley, Bruce C., et al.
Publicado: (2014)

Roles of Sorcin in Drug Resistance in Cancer: One Protein, Many Mechanisms, for a Novel Potential Anticancer Drug Target
por: Battista, Theo, et al.
Publicado: (2020)

How and when does an anticancer drug leave its binding site?
por: Tiwary, Pratyush, et al.
Publicado: (2017)

Hydrolytic stability of anticancer drugs and one metabolite in the aquatic environment
por: Toński, Michał, et al.
Publicado: (2021)

A New Look into the Mode of Action of Metal-Based Anticancer Drugs
por: Marques, M. Paula M., et al.
Publicado: (2020)

Photoactivatable Platinum-Based Anticancer Drugs: Mode of Photoactivation and Mechanism of Action
por: Dai, Ziwen, et al.
Publicado: (2020)

ZFAS1: a long noncoding RNA associated with ribosomes in breast cancer cells
por: Hansji, Herah, et al.
Publicado: (2016)

Endocrine Therapy of Estrogen Receptor-Positive Breast Cancer Cells: Early Differential Effects on Stem Cell Markers
por: Leung, Euphemia Y., et al.
Publicado: (2017)

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
por: Stones, Clare J., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_sss9uhapr8sldrenl6qfm1b8ed